Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Announces Full Exercise of Underwriter's Option to Purchase Additional Shares
SOLANA BEACH, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the underwriter of its previously announced public offering of approximately 2.4 million shares of
View HTML
Toggle Summary Evoke Pharma Announces Pricing of Public Offering of Common Stock
SOLANA BEACH, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that it has priced an underwritten public offering of 2,413,793 shares of its common stock at a price to
View HTML
Toggle Summary Evoke Pharma Announces Proposed Public Offering of Common Stock
SOLANA BEACH, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it intends to offer and sell shares of its common stock in a "firm commitment" underwritten
View HTML
Toggle Summary FDA Exempts Evoke from Requirement for Human Factor Validation Study
Company reaffirms NDA submission by year end 2017
View HTML
Toggle Summary Evoke Pharma to Attend 2017 JPMorgan Healthcare Conference
SOLANA BEACH, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer, and its Chief Business Officer, Matt
View HTML
Toggle Summary Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial
Nausea and abdominal pain symptoms significantly reduced in patients with higher symptom severity
View HTML
Toggle Summary Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti
Healthy volunteer bridging study to oral metoclopramide to be completed and submitted in NDA with existing safety and efficacy data
View HTML
Toggle Summary Evoke Pharma Reports Third Quarter 2016 Results
SOLANA BEACH, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2016.
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2016 Financial Results
SOLANA BEACH, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the third quarter 2016 on Wednesday, November 9, 2016,
View HTML
Toggle Summary Evoke Pharma Announces Positive Non-Clinical Pre-NDA Meeting with FDA for Gimoti
SOLANA BEACH, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced that it has completed a pre‑New Drug Application (NDA) meeting with the U.S.
View HTML